A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults
<p>We assessed S-268019-b, a recombinant spike protein vaccine with a squalene-based adjuvant, for superiority in its immunogenicity over ChAdOx1 nCoV-19 vaccine among adults in Japan. In this multicenter, randomized, observer-blinded, phase 3 study, severe acute respiratory syndrome...
Main Authors: | Iwata, S, Pollard, AJ, Tada, Y, Omoto, S, Shibata, RY, Igarashi, K, Hasegawa, T, Ariyasu, M, Sonoyama, T |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Springer Nature
2024
|
Similar Items
-
ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates - author's reply
by: Voysey, M, et al.
Published: (2021) -
ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 – Authors' reply
by: Voysey, M, et al.
Published: (2020) -
ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. Reply
by: Madhi, SA, et al.
Published: (2021) -
Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
by: Ogbe, A, et al.
Published: (2022) -
Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan
by: Takuhiro Sonoyama, et al.
Published: (2023-12-01)